CB Scientific, Inc., a designer, developer and manufacturer of Cannabis Analytical Tools and Devices, Cannabis Medical Delivery Systems and Personal Analytical Kits and Devices, announces today that the Company has developed a novel product medical device portfolio since acquiring Marutronics Medical Devices in February 2017. The company has developed three core platform technologies; CannaRAPID™, CannaNASAL™, and CannaDERME™, focused on precise dosing and controlled release of cannabinoid compounds for patients. CB Scientific developed CannaRAPID™, a sublingual cannabinoid delivery product, and is gearing up for clinical studies on the use of CannaRAPID™ for treating opioid addiction.
United States is in the middle of an unprecedented opioid epidemic; Since 1999, the rate of overdose deaths involving opioids nearly quadrupled, and over 165,000 people have died from prescription opioid overdoses. Prescription pain medication deaths remain far too high, and in 2014, the most recent year on record, there was a sharp increase in heroin-involved deaths and an increase in deaths involving synthetic opioids such as fentanyl. Prevention, treatment, and research to rapidly tackle and reverse opioid overdoses are critical to fighting this epidemic.
Early data coming out of states where marijuana laws have been passed suggest that even as conventionally used, marijuana may be playing a role in offsetting the opioid addiction epidemic. Studies have shown that phytocannabinoids like cannabidiol have promising results in opioid withdrawal symptoms and heroin-seeking behavior. Our studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. There are at least partial evidence that cannabinoid compounds can even relieve depression. CB Scientific is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of CannaRAPID™ for opioid addiction.
„Data is showing that on an average day in US about 78 people die from an opioid-related overdose, most of the ones died belongs to the younger population,” said Bobban Subhadra, M.S., Ph.D, Chief Operating Officer of CB Scientific. „This is a serious epidemic that needs to be addressed with a high level of urgency; we are talking about teens who are the future of our nation dying in high numbers on our streets. That is the reason, why we at CB Scientific, want to seriously invest in CannaRAPID™ as a possible intervention for opioid addiction. Even if we can save one young life with our CannaRAPID™ sublingual technology, we will take it as a enormous success,” he added.
CB Scientific’s sublingual product, CannaRAPID™ is a sugar-free orally disintegrating tablet to deliver precise dose of cannabinoids to neural tissues in a matter of seconds. The formulation is optimized with nanotechnology and tissue permeation enhancing molecules for faster absorption. CB Scientific is pairing up with clinical organizations and various clinical practitioners for conducting clinical studies using CannaRAPID™ for various indications such as stress and anxiety relief, cognitive focus, various kinds of pain, migraines etc. There are several inherent benefits of sublingual delivery of drugs such as fast absorption, avoidance of unwanted liver and gut microbiota metabolism on active drug. Further, as medical cannabis is going to be on mainstream medicine in the not so distant future, there is an urgent need for a new dosage and delivery mechanism that can improve patient compliance.